News und Analysen
Correction of a release from 04.12.2025 17:56 CET/CEST - BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
BILENDI: Proprietary Market Research Panels in 44 Countries, Supported by the Highest Quality Standards
BILENDI: 2025 revenue as of 30 September: €64.5 million, up +42.9%
BILENDI: New record results in the first half of 2025 • Historic half-yearly EBITDA margin of 20.6 % (+1.9 pt) • Adjusted operating profit up +87 %
BILENDI: Revenue for the first half of 2025: €43.5 million, up +42.2%
Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis® LCS
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
BILENDI: Bilendi celebrates 20 years of stock market listing. From a French pioneer to a global Group
Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
Correction of a release from 12.05.2025 17:37 CET/CEST - Revenue for Q1 2025: 19.7 M€, up +36.5%
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
BILENDI: Q1 2024 revenues up +4.6% at €14.5 million
Median Technologies Reports Full-year 2024 Financial Results
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software
eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study
Regulatory News:
Median Technologies (Paris:ALMDT) (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI)
Correction of a release from 26.03.2025 17:37 CET/CEST - BILENDI: Record results in 2024
Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software
BILENDI: Bilendi in 2024: a year of transformation and major strategic breakthroughs
Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software
BILENDI: The latest version of Bilendi Discuss fully automates market research studies from initial objective to final report using AI
BILENDI: Bilendi announces the completion of the acquisition of Netquest
Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
Regulatory News:
Median Technologies (Paris:ALMDT):
Fredrik Brag, CEO of Median Technologies, will host two webcasts on February 4, 2025
“New Horizons in Fighting Lung Cancer: eyonis™ LCS
Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device